Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity

BACKGROUND: We previously reported preliminary results of our phase I study of continuous daily sorafenib with bevacizumab every other week for solid tumours. Toxicity was moderate, leading to additional dose levels (DL) testing intermittent sorafenib dosing. METHODS: Seventeen patients with advance...

Fuld beskrivelse

Na minha lista:

Bibliografiske detaljer
Main Authors:	Lee, J-M, Sarosy, G A, Annunziata, C M, Azad, N, Minasian, L, Kotz, H, Squires, J, Houston, N, Kohn, E C
Format:	Artigo
Sprog:	Inglês
Udgivet:	Nature Publishing Group 2010
Fag:	Clinical Study
Online adgang:	https://ncbi.nlm.nih.gov/pmc/articles/PMC2822947/ https://ncbi.nlm.nih.gov/pubmed/20051952 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605514
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!

Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity

Lignende værker